Risk factors for rifampin mono-resistant tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 6 PART I, 1998, Pages 1881-1884

  Ridzon, Renée ^a   Whitney, Cynthia G ^b   McKenna, Matthew T ^b   Taylor, Jeffery P ^b   Ashkar, Susan H ^b   Nitta, Annette T ^b   Harvey, Sydney M ^b   Valway, Sarah ^b   Woodley, Charles ^b   Cooksey, Robert ^b   Onorato, Ida M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; RIFABUTIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS;

EID: 17444442465     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.6.9712009     Document Type: Article

References (33)

1. Mitchison, D. A., and A; J. Nunn. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis. 133:423-430.
2. American Thoracic Society. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
3. Bloch, A. B., G. M. Cauthen, I. M. Onorato, K. G. Dansbury, G. D. Kelly, C. R. Driver, and D. E. Snider, Jr. 1994. Nationwide survey of drug-resistant tuberculosis in the United States. J.A.M.A. 271:665-671.
4. Carpels, G., K. Fissette, V. Limbana, A. Van Deun, W. Vandenbulcke, and F. Portaels. 1995. Drug resistant tuberculosis in sub-Saharan Africa: an estimation of incidence and cost for the year 2000. Tubercle 76:480-486.
5. Githui, W. A., D. Kwamanga, J. M. Chakaya, F. G. Karimi, and P. G. Waiyaki. 1993. Anti-tuberculosis initial drug resistance of Mycobacterium tuberculosis in Kenya: a ten-year review. East Afr. Med. J. 70:609-612.
6. Blanchard, J. S. 1996. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem. 65:215-239.
7. Musser, J. M. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8:496-514.
8. Burwen, D. R., J. L. Jones, and TB/HIV Surveillance Group. 1995. Epidemiology and diagnosis of tuberculosis (abstract). Am. J. Respir. Crit. Care Med. 151(Suppl.):A144.
9. Weltman, A. C., S. P. Righi, G. T. DiFerdinando, R. J. Jovell, and J. R. Driscoll. 1995. Rifampin-resistant Mycobacterium tuberculosis. Lancet 345:1513.
10. Nolan, C. M., D. L. Williams, M. D. Cave, K. D. Eisenach, H. el-Hajj, T. M. Hooton, R. L. Thompson, and S. V. Goldberg. 1995. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am. J. Respir. Crit. Care Med. 152:1067-1071.
11. Bishai, W. R., N. M. Graham, S. Harrington, C. Page, K. Moore-Rice, N. Hooper, and R. E. Chaisson. 1996. Rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N. Engl. J. Med. 334:1573-1576.
12. Bradford, W. Z., J. N. Martin, A. L. Reingold, G. F. Scheeter, P. C. Hopewell, and P. M. Small. 1996. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco. Lancet 348:928-931.
13. van Embden, J. D., M. D. Cave, J. T. Crawford, J. W. Dale, K. D. Eisenach, B. Gicquel, P. Hermans, C. Martin, R. McAdam, T. M. Shinnick, and P. M. Small. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409.
14. Chaves, F., Z. Yang, H. el Hajj, M. Alonso, W. J. Burman, K. D. Eisenach, F. Dronda, J. H. Bates, and M. D. Cave. 1996. Usefulness of sec-ondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis. J. Clin. Microbiol. 34:1118-1123.
15. Kent, P. T., and G. Kubica. 1985. Public Health Mycobacteriology: A Guide for the Level III Laboratory. U.S. Department of Health and Human Services, Centers for Disease Control, Atlanta. 159-184.
16. Kapur, V., L. L. Li, S. Iordanescu, M. R. Hamrick, A. Wanger, B. N. Kreiswirth, and J. M. Musser. 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase B subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.
17. Dean, A. G., J. A. Dean, A. H. Burton, and R. C. Dicker. 1990. Epi Info, Version 5: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, GA.
18. EGRET. 1993. Statistics and Epidemiology Research Corporation, Seattle, WA.
19. Jarallah, J. S., A. K. Elias, A. Hajjaj, M. S. Bukhar, A. Shareef, and S. A. Al-Shammari. 1994. High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia. Tubercle 73:113-115.
20. Lutfey, M., P. Della-Latta, V. Kapur, and L. A. Palumbo. 1996. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med. 153:837-840.
21. Munsiff, S. S., and T. R. Friedan. 1996. Mono-rifampin resistant tuberculosis, New York City, 1993-1994 (abstract no. C118). In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans, LA). American Society for Microbiology, Washington, DC. 55.
22. Reichman, L. B., R. J. McDonald, and B. T. Mangura. 1994. Rifabutin prophylaxis against Mycobacterium avium complex infection. N. Engl. J. Med. 330:437-438.
23. Berning, S. E., G. A. Huitt, M. D. Iseman, and C. A. Peloquin. 1992. Malabsorption of antituberculosis medication by a patient with AIDS. N. Engl. J. Med. 327:1817-1818.
24. Patel, K. B., R. Belmonte, and H. M. Crowe. 1995. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N. Engl. J. Med. 332:336-337.
25. Gordon, S. M., C. R. Horsburgh, Jr., C. A. Peloquin, J. A. Havlik, Jr., B. Metchock, L. Heifets, J. E. McGowan, Jr., and S. E. Thompson, 3rd. 1993. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J. Infect. Dis. 168:1559-1562.
26. Sahai, J., K. Gallicano, L. Snick, S. Tailor, G. Garber, I. Seguin, L. Oliveras, S. Walker, A. Rachlis, and D. W. Cameron. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293.
27. Peloquin, C. A., A. T. Nitta, W. J. Burman, K. F. Brudney, J. R. Miranda-Massari, M. E. McGuinness, S. E. Berning, and G. T. Gerena. 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30:919-925.
28. Trapnell, C. B., P. K. Narrowing, R. Li, and J. P. Lavelle. 1996. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med. 124:573-576.
29. Narang, P. K., C. B. Trapnell, J. R. Schoenfelder, J. P. Lavelle, and J. R. Bianchine. 1994. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330:1316.
30. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, and A. T. Walker. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 230:545-550.
31. Horsburgh, Jr., C. R. 1996. Advances in the prevention and treatment of Mycobacterium avium disease. N. Engl. J. Med. 335:428-429.
32. Pierce, M., S. Crampton, D. Henry, L. Heifets, A. LaMarca, M. Montecalvo, G. P. Wormser, H. Jablonowski, J. Jemsek, M. Cynamon, B. G. Yangco, G. Notario, and J. C. Craft. 1996. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335:384-391.
33. Havlir, D. V., M. P. Dube, F. R. Sattler, D. N. Forthal, C. A. Kemper, M. N. Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, Jr., M. D. Witt, S. A. Bozzette, and J. A. McCutchan. 1996. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N. Engl. J. Med. 335:392-398.